Skip to content

503A vs 503B Bulk Substances: Supplier Requirements

How federal compounding rules in sections 503A and 503B shape what bulk drug substance suppliers and pharmacy buyers must document. Not legal advice.

Updated 7 min read

This guide is general information, not legal or regulatory advice. The rules summarized here are federal statutes and agency policies that change, and state law adds its own requirements. A pharmacy, outsourcing facility or supplier should get its own legal advice before relying on any statement below. We describe what the statutes say and link to them so you can read the text yourself.

Why do suppliers and pharmacies ask each other for documents?

Because both federal compounding pathways attach conditions to the bulk drug substances a compounder uses, and those conditions have to be shown on paper. Section 503A and section 503B of the Federal Food, Drug, and Cosmetic Act are the two main federal pathways under which compounded human drugs are exempt from certain requirements that apply to manufactured drugs. Both pathways place conditions on the bulk drug substances (the active ingredients) a compounder may use. Those conditions create the paperwork that flows between a pharmacy and an ingredient supplier. If you are a pharmacy buyer, this is the reason a supplier asks for your license and tells you what documents come with the material. If you are a supplier, this is why your customers ask about your registration and your certificates.

What does section 503A require of bulk drug substances?

Section 503A sets conditions on each bulk drug substance used by a state-licensed pharmacy or physician: a monograph, approved-drug or list basis, a registered manufacturer and a certificate of analysis. It is the pathway for compounding by a licensed pharmacist or physician. Reading the statute at 21 U.S.C. 353a, the conditions on bulk drug substances include that each one:

  • complies with the standards of an applicable United States Pharmacopeia or National Formulary monograph, if one exists, and with the USP chapter on pharmacy compounding;
  • if no monograph exists, is a component of a drug approved by FDA, or appears on a list developed by FDA through rulemaking; and
  • is manufactured by an establishment registered under section 510 of the Act, and is accompanied by valid certificates of analysis for each bulk drug substance.

FDA's page on bulk drug substances used in compounding under 503A restates these routes and describes an interim policy that sorts nominated substances into categories. In FDA's description, substances in one category may be eligible for the list and nominated with enough information, while another category covers substances FDA has flagged for significant safety risks; for those, FDA says it would consider enforcement under its general policies. The page also encourages compounders to know their bulk supplier, meaning to verify where ingredients come from.

FDA also maintains a separate page of certain bulk drug substances that may present significant safety risks. On that page FDA discusses concerns for several peptides, such as possible immunogenicity from aggregation or impurities, and difficulty in characterizing the active ingredient and its impurities. Whether any particular peptide may lawfully be compounded depends on its status under the statute and on FDA's current lists and policies, which a pharmacy's counsel should check at the time of purchase.

What does a 503A buyer-supplier exchange look like?

In practice, the pharmacy and the supplier trade a short, predictable set of documents.

A pharmacy buying a bulk substance can expect to be asked for, or to ask for:

  • the pharmacy's license and, as applicable, state board details;
  • the supplier's FDA establishment registration information;
  • a certificate of analysis for the specific lot;
  • evidence the substance meets the monograph, if one exists, or the basis on which it qualifies without one;
  • traceability: lot number, manufacturer, and chain of custody.

Each of these is a question the pharmacy has to be able to answer for itself. A supplier can supply documents, but the compounding conditions fall on the compounder.

What does section 503B require of outsourcing facilities?

Section 503B applies to outsourcing facilities, which register with FDA, and it sets its own conditions on bulk drug substances: a list or shortage basis, compendial compliance where a monograph exists, a registered manufacturer and a valid certificate of analysis. It creates the category of outsourcing facility, which registers with FDA and is subject to current good manufacturing practice requirements for the drugs it makes. The statute at 21 U.S.C. 353b sets conditions where an outsourcing facility uses bulk drug substances. Paraphrasing the text, a facility that compounds with bulk drug substances must meet conditions that include:

  • the substance appears on a list established by FDA of bulk drug substances for which there is a clinical need, or the drug made from it appears on FDA's drug shortage list when it is compounded, distributed and dispensed;
  • if a monograph exists in the USP, NF or another recognized compendium, the substance complies with it;
  • the substance is made by an establishment registered under section 510; and
  • the substance is accompanied by a valid certificate of analysis.

The statute also requires outsourcing facilities to report periodically to FDA on the drugs they compound, including active ingredients and their sources. That reporting is one more reason an outsourcing facility will ask a supplier to identify the origin of the material precisely.

What do 503A and 503B have in common for suppliers?

Both pathways come down to a registered manufacturer, a valid certificate of analysis and a substance with a recognized status. Reading the two statutes side by side, three themes recur for suppliers:

  1. Registered manufacturer. The establishment that made the substance has to be registered with FDA. Suppliers who are resellers should be able to say who the registered manufacturer is.
  2. Valid certificate of analysis. A COA is a legal condition in both pathways, not a courtesy. What makes one "valid" is something for counsel and the quality unit to decide. The checklist in what a batch COA should contain covers its technical content, and the glossary defines the term.
  3. Pharmacopeial or listed status. Whether a substance has a monograph, is on a list, or neither decides whether a compounder can use it. A supplier cannot change a substance's status by describing it differently.

What should a pharmacy ask an API supplier?

Ask the questions below in writing and keep the answers in the supplier file.

  • What is the FDA establishment registration of the site that manufactured the lot, and can you show it?
  • Will each lot arrive with a certificate of analysis, and what methods does it cite?
  • Does a USP or NF monograph exist for this substance, and does your material comply?
  • Can you trace the lot back to the manufacturer and through every handler?
  • How will you notify us of any change in site, route or specification?
  • Do you label the product for compounding, or for research only? A product labeled for laboratory research may not satisfy a compounder's source requirements. See what research-use-only labeling means.

What should a supplier ask a pharmacy?

A supplier should confirm the buyer's pathway and license, and how it will keep lot records.

  • Which pathway do you operate under, and what is your license?
  • What is the intended handling of the material under your own legal advice?
  • What documents does your quality system require with each lot?
  • How will you record lot and supplier information, so a recall can reach you? See lot traceability and record keeping.

Does this guide say any peptide qualifies for compounding?

No. It does not say any peptide on our site qualifies for compounding. The compound pages, for example sermorelin, tesamorelin, thymosin alpha-1 and CJC-1295 (without DAC), are research references. Whether a given substance is eligible under 503A or 503B is a legal question for the compounder and its counsel, and it can change as FDA updates lists and policies.

What did FDA change in 2025 and 2026?

Two FDA actions are worth knowing about. Read the pages directly, because FDA may update them.

  • Nominations on or after January 7, 2025. FDA's 503A bulk drug substances page states that FDA does not intend to place bulk drug substances nominated on or after January 7, 2025 into the categories of its interim policy. Earlier nominations keep their categories; category 1 substances may stay under the interim policy until FDA acts.
  • Proposed 503B exclusion. On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, stating that it found no clinical need for outsourcing facilities to compound these drugs from bulk substances. This is a proposal. Comments closed July 30, 2026, after FDA extended the original June 30 deadline; check FDA's page for any final action.

Neither item is legal advice, and neither says anything about a particular supplier. They show why a pharmacy's counsel should check FDA's pages at the time of each purchase.

What are the practical next steps?

Start with counsel, then build the supplier file.

  1. Have counsel confirm which pathway and which lists apply to the substance you plan to buy.
  2. Build a supplier qualification file as described in how to vet a bulk peptide supplier.
  3. Ask for registration evidence and lot COAs before the first order.
  4. Keep records long enough to meet your license and state requirements.

For an overview of how we handle pharmacy account inquiries, see the pharmacy APIs page. The application page lists what we ask of new accounts. Neither page replaces the legal review described above.

How Bulk Peptides Co handles this

Bulk Peptides Co supplies pharmacy APIs only after verifying the buying pharmacy's license, and the pharmacy APIs page explains how a pharmacy applies. Every lot is tested by an independent third-party laboratory, Freedom Diagnostics or ILS Labs, with HPLC for purity and mass spectrometry for identity, and the lot COA belongs in your supplier file once it is posted. That COA does not settle the registration, monograph or list questions above, which stay with your counsel and quality unit.

Questions

What is a 503B pharmacy?

Section 503B of the Federal Food, Drug, and Cosmetic Act covers outsourcing facilities, which register with FDA and follow current good manufacturing practice. People often search for 503B pharmacies, but the statute's term is outsourcing facility.

What does the 503A bulk drug substances list govern?

Under 503A, a bulk drug substance without a USP or NF monograph must be a component of a drug approved by FDA or appear on a list FDA develops through rulemaking. FDA describes these routes on its page about bulk drug substances used in compounding under section 503A.

What are FDA's 503A interim policy categories?

FDA's interim policy sorts bulk drug substances nominated for the 503A list into categories. One covers substances that may be eligible for the list when nominated with enough information; another covers substances FDA has flagged for significant safety risks. Check FDA's page for the current definitions.

What is the difference between 503A and 503B?

Section 503A covers compounding by state-licensed pharmacists and physicians. Section 503B covers FDA-registered outsourcing facilities that follow current good manufacturing practice. Each sets its own conditions on bulk drug substances.

Does a certificate of analysis matter under both pathways?

Yes. Both statutes condition the use of a bulk drug substance on its being accompanied by a valid certificate of analysis, and on a manufacturer registered under section 510.

Sourcing for a business?

Approved buyers see wholesale pricing and order online. Uploaded lot COAs are public on each compound page.